VAR-200 is under clinical development by ZyVersa Therapeutics and currently in Phase I for Focal Segmental Glomerulosclerosis (FSGS). According to GlobalData, Phase I drugs for Focal Segmental Glomerulosclerosis (FSGS) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the VAR-200 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VAR-200 overview
VAR-200 is under development for the treatment of focal segmental glomerulosclerosis (FSGS), alport syndrome and in patients with type 2 diabetic kidney disease and proteinuria. The drug candidate is a hydroxypropyl beta-cyclodextrin comprised of seven sugar molecules bound together in a ring (cyclic oligosaccharide). It acts by targeting ABCA1 and ABCG1. It is administered through intravenous route.
ZyVersa Therapeutics overview
ZyVersa Therapeutics is developing drugs for treating inflammatory and kidney diseases. The company is headquartered in Weston, Florida, the US.
For a complete picture of VAR-200’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
